FDA’s REMS Program: How It Can Hurt – or HELP – your Drug
Guidance for a smooth approval process & working successfully with the new requirements
FDA's new power to require Risk Evaluation and Mitigation Strategies (REMS) as part of a drug’s approval could be the most important change to FDA’s authority in the last 20 years. The questions for drug sponsors are abundant: How often are REMS provisions required for new drugs? What could trigger a REMS requirement for my drug? What types of REMS provisions are typically required? At what stage of drug development should I start planning for REMS? Will my drug be delayed while I negotiate REMS requirements with FDA? Are there any commercial opportunities I can turn to my advantage from having a REMS?
In this Special Report, you get answers to all these questions and many more, from our analysis of the most important REMS programs to date, to the specific regulatory and commercial experiences of the first companies to go through the REMS process.
This detailed 43-page report includes critical information for regulatory, legal, R&D, and business development executives, and anyone who works for or with biopharma companies to meet the new REMS requirements. Get this exclusive report now! Follow this link for details.
